Skip to content
Medical Health Aged Care

Introducing a less embarrassing skin cancer check

Skintel 2 mins read

Introducing a less embarrassing skin cancer check

First of its kind in Victoria

 

Skin cancer checks save lives by enabling early detection and treatment but they can be embarrassing and uncomfortable for patients. Skintel, a new clinic on St Kilda Road, offers an innovative way to see skin differently using state-of-the-art technologies like Body Map and optical biopsy. 

 

 “Skintel is the only clinic in Victoria offering confocal microscopy, a breakthrough, non-invasive technology for skin cancer diagnosis. We are thrilled to offer our patients a new type of skin cancer check that delivers results almost instantly,” said Skintel’s founder, Dr Maxton Bergin, who holds a Master’s degree in Skin Cancer Medicine from UQ, is accredited with the Skin Cancer College of Australasia.

 

Evidence suggests that patients find traditional skin cancer checks embarrassing and uncomfortable, which can discourage participation. A traditional approach requires patients to lie in their underwear while a doctor closely examines every single mole. Suspicious moles must be surgically biopsied at a follow-up appointment and then sent to the lab, triggering an anxious 1-2 week wait for results. 

 

“Traditional biopsies can be stressful for patients,” acknowledges Dr Bergin. “Our approach changes that. There’s only a couple of minutes in your underwear while our scanners map your moles. If we identify a suspicious mole, we use a non-invasive optical biopsy, which provides an immediate diagnosis.”

 

Skintel offers a high-tech approach to skin cancer checks using: 

  • Body Map –  an AI-powered scan of every mole, identifying those that merit a closer look. This takes just a few minutes and then patients can get dressed.

  • Dermoscopy – a closer look at certain moles using 200X magnification (a little like looking through the surface of the ocean wearing polarised sunglasses)

  • Optical biopsy (confocal microscopy) – if clinically indicated, we explore below the skin in 3D at up to 550x magnification (a little like going scuba diving), sparing patients the discomfort and downtime associated with surgical biopsies.

 

“Optical biopsy means we can look at cells, blood vessels and connective tissue in 3D without cutting into the skin,” said Dr Bergin. “It’s non-invasive with no risk of pain or scarring – ideal for patients with suspicious moles on the face. It’s highly effective at diagnosing melanoma and reducing unnecessary surgical biopsies. And it delivers instant results, saving patients an anxious wait.”

 

To learn more or book a skin cancer check, visit www.skintel.au.  

–-Ends–-


About us:

Skintel is at the forefront of innovation in skin cancer detection, combining high-tech artificial intelligence with the human expertise of our doctors and melanographers. You can rest assured that every visible mole on your body has been checked three times.


Contact details:

Dr Maxton Bergin

Phone 1800 929 929

More from this category

  • Medical Health Aged Care
  • 21/05/2026
  • 22:17
Merck

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer

Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority…

  • Contains:
  • Medical Health Aged Care
  • 21/05/2026
  • 21:18
Baszucki Group

Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis

Randomized controlled trial will evaluate both symptom progression and underlying biology SAN MATEO, Calif.–BUSINESS WIRE– Baszucki Group today announced a £1.17 million grant to…

  • Contains:
  • Medical Health Aged Care
  • 21/05/2026
  • 20:47
Sinovac Biotech Ltd.

SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend

BEIJING--BUSINESS WIRE-- Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.